ILTS INSIGHTS: Antibody-mediated rejection: diagnosis, treatment, and outcomes
Anthony J. Demetris, Jacqueline O’Leary, Abraham Shaked discuss the different types of rejection as well as new tools for diagnosis and best therapeutic options.
This webinar focusses on the different types of rejection, as well as new tools for diagnosis and the best therapeutic options. Despite the improvement of immunosuppression strategies, allograft rejection remains an issue affecting liver transplant recipients. Markers of rejection can improve early diagnosis and can help to tailor immunosuppression. Antibody-mediated rejection is increasingly recognized after LT – however, its prevention, diagnosis, and treatment are still challenging.
This webinar is organized by the Liver Transplant Immunology SIG & Precision Medicine and Biomarkers in Liver Transplantation SIG.
Objectives: Explain the histological characteristics of antibody-mediated rejection; understand the role of preformed and de novo donor-specific antibodies in antibody-mediated rejection, discuss treatment options to prevent and treat antibody-mediated rejection and follow-up
- Pathology in antibody-mediated rejection (Anthony J. Demetris)
- Relevance of preformed and de novo donor-specific antibodies (Jacqueline O’Leary)
- Treatment and outcomes of antibody-mediated rejection (Abraham Shaked)
|Anthony J. Demetris is the Director of the Division of Liver and Transplantation Pathology and also the Research Histology Shared Resource Laboratory of the University of Pittsburgh. He is a member of the McGowan Institute for Regenerative Medicine, Chairman of the IRB Risk Management Committee, and a member of the Thomas E. Starzl Transplant Institute IT Steering Committee.
|Jacqueline O’Leary is the Chief of Hepatology at the Dallas VA Medical Center. Her research focuses on Acute-on-Chronic Liver Failure transplant and Antibody Mediated Rejection post-transplant. She received an MD at UCSF with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern, Dr. O’Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research at Harvard focused on immunology.
|Abraham Shaked is the Professor of Surgery at the University of Pennsylvania and Director of the Penn Transplant Institute. He is a nationally and internationally recognized leader in the field of transplantation, serving as President of the American Society of Transplant Surgeons. His specialty is focused on adult and pediatric liver transplantation, complex hepatobiliary surgery, biliary reconstruction, and minimization of immunosuppression.|
|Geoff McCaughan is the Director of the Australian National Liver Transplant unit at RPAH, and the University of Sydney, a member of the Faculty at the Centenary Institute and head of the Hepatitis and Liver Cancer Program in the Institute. He also heads a clinical research program as Director of the AW Morrow Gastroenterology and Liver Centre. He is a topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group.
|Eleonora De Martin is a Hepatologist at Centre-Hépato-Biliaire, Paul Brousse Hospital, France. Her fields of expertise are liver transplantation, autoimmune hepatitis in particular severe acute forms with LT indication and hepatic toxicity of immunotherapy for metastatic cancer. She is the Chair-elect of the ILTS Vanguard Committee and topic coordinator of the ILTS Liver Transplant Immunology Special Interest Group.|
This webinar is supported by: Chiesi Farmaceutici S.p.A.
The production of this webinar was made possible with the unconditional grant of Chiesi Farmaceutici. Chiesi has had no influence on the content, and full editorial control remains the sole responsibility of ILTS.
|Chiesi is an international company based in Parma, Italy, with more than 85 years of experience and a strong focus on research, development, production, and the commercialisation, of innovative medicines in the Respiratory, Neonatology, Rare Disease, and Special Care Therapeutic Areas. Since 2019, Chiesi is the largest global pharmaceutical group awarded with B Corp certification, recognition of the highest standards of social and environmental performance and transparency.|